Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Surprised

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Sep 11, 2023 1:04pm

122 Views

Post# 35629659

RE:RE:RE:RE:RE:Surprised

Marathon will be a problem until it is taken out ..
They have a lien on all the assets and the carryng cost is very costly.

It needs to be taken out completely or at least reduced substantially even if TH do not find a partner.... Increasing sales of the legacy drugs would /will mean increased cash generation which will lead to higher SP allowing for a 5-10 % dilutive financing to reduce the amount due to Marathon...
We are not there yet but I hope that moment comes in the not too distant future...